Precision radiation boost aims to tame High-Risk prostate cancer

NCT ID NCT05628363

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a precise radiation technique called adaptive SBRT for men with high-risk or unfavorable intermediate-risk prostate cancer. The treatment targets the prostate and pelvic lymph nodes while giving an extra radiation boost to tumor spots seen on MRI. The goal is to see if this approach is safe and feasible, with fewer than 15% of the 28 participants experiencing severe urinary or bowel side effects within 90 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
radiation therapy (SBRT) and androgen deprivation therapy (ADT)
What this could lead to
If successful, this approach could offer a more precise, shorter radiation course for high-risk prostate cancer, potentially reducing side effects while effectively targeting tumors.
What could go wrong
This is a small, early-phase trial (28 participants) focused on safety, not yet proving effectiveness. Side effects from radiation and ADT, such as urinary or bowel issues, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER OF THE PROSTATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.